A Randomized, Double-blind, Placebo-controlled Pilot Trial of Low-intensity Pulsed Ultrasound Therapy for Refractory Angina Pectoris

doi:10.21203/rs.3.rs-2119641/v1

Download PDF

Article

A Randomized, Double-blind, Placebo-controlled Pilot Trial of Low-intensity Pulsed Ultrasound Therapy for Refractory Angina Pectoris

https://doi.org/10.21203/rs.3.rs-2119641/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Despite the advances in the treatment of cardiovascular diseases, effective treatment remains to be established to improve the quality of life of patients with chronic coronary syndrome. The aim of this study was to evaluate the effectiveness and safety of the low-intensity pulsed ultrasound (LIPUS) therapy, which we have developed as a novel non-invasive angiogenic therapy. We conducted a randomized, double-blind, placebo-controlled (RCT) pilot trial of the LIPUS therapy for patients with refractory angina pectoris without indication for PCI or CABG despite optimal medical therapy. The primary endpoint, the changes in weekly use of nitroglycerin were comparable; -3.06 (95% CI: -4.481 to -1.648) in the LIPUS group and − 3.10 (95% CI: -4.848 to -1.356) in the placebo group (both P < 0.01). In the present study, the LIPUS therapy did not further ameliorate chest pain as compared with optimal medications alone in patients with refractory angina pectoris (Registration ID: UMIN000012369).

Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are established treatments for acute coronary syndrome.¹ On the other hand, regarding chronic coronary syndrome, current evidence is not still enough for physicians to select a proper treatment strategy.² The COURAGE and the ISCHEMIA trials have demonstrated that invasive treatment strategy may provide no additional prognostic benefits on the top of optimal medical therapy for chronic coronary syndrome.^3,4 These results may be caused by procedure-related complications of PCI or CABG, high-risk of bleeding due to dual-antiplatelet therapy (DAPT) or the presence of coronary microvascular dysfunction that are not ameliorated by PCI or CABG. Especially, patients with refractory angina without indication of PCI or CABG despite optimal medical therapy could be regarded as a high-risk population with poor prognosis and therefore require a further therapeutic option. Furthermore, the ORBITA trial demonstrated that PCI for a single-vessel disease (> 70% stenosis in the left anterior descending coronary artery) has no additional benefits for exercise tolerance as compared with placebo group.⁵ This study suggests that much of symptomatic improvements after PCI may be due to placebo effects.⁵ Thus, effective therapeutic strategy to improve quality of life (QOL) and prognosis of patients with refractory angina remains to be established.

We have developed a low-intensity pulsed ultrasound (LIPUS) therapy as a novel, non-invasive angiogenic therapy, which upregulates endothelial nitric oxide synthase (eNOS) and other angiogenic factors selectively in ischemic tissues.⁶ Pulsed ultrasound with specific conditions has been reported to exert therapeutic effects, such as cell proliferation and anti-inflammatory responses.^7,8 Mechanistically, by physically inducing cyclic strain, LIPUS stimulates caveolae that locate on the surface of endothelial cell membrane.^9,10 We demonstrated that LIPUS phosphorylates Ser1177 of eNOS under the presence of caveolae, and subsequent phosphorylation of downstream Akt and Erk1/2 upregulates eNOS and VEGF expressions.¹¹ This therapeutic mechanism is called as “mechano-transduction”.^12–14 Clinical application of the mechano-transduction mechanism could be expected as a safe and highly effective local treatment strategy.¹⁴

In the present study, we conducted a randomized, double-blind, placebo-controlled pilot trial in order to address the efficacy and safety of the LIPUS therapy for patients with refractory angina without indication of PCI or CABG.

Study Protocols

We enrolled patients with refractory angina without indication of PCI or CABG despite optimal medical therapy, who had angina episode at least once a week. They were enrolled in 2013–2018, and were able to regularly visit an outpatient clinic. The registration of this study was extended from 3 years to 6 years because of the interruption of funding source midway through. All patients gave an informed consent. They were randomly assigned to either the LIPUS group or the placebo group in a 1:1 fashion, according to the following 4 allocation factors; Canadian Cardiovascular Society (CCS) class score (II, III or IV), weekly use of nitroglycerin (4 times a week or less, or 5 times a week or more), left ventricular ejection fraction (40% or more, or less than 40%), and participating hospital. In order to avoid any possible pathological angiogenesis, patients with malignancies or uncontrolled diabetic retinopathy were excluded. The diagnosis and approval of enrollment were made by a third-party committee. After we confirmed patient's eligibility, subject information was sent to the registration center, randomized allocation was performed, and then the allocation results were documented to the open-label treatment physicians at each institution. In this study, all participating physicians and supporting staff except un-blinded physician who handled the LIPUS or placebo procedure were blinded. This study was conducted at 10 major cardiovascular institutes in Japan, including Kumamoto University Hospital, Kurume University Hospital, Hyogo Medical University Hospital, Fujita Health University Hospital, Tokyo Women’s Medical University Hospital, Nihon University Hospital, Tokyo Medical University Hospital, Juntendo University Hospital, National Cerebral and Cardiovascular Center, and Tohoku University Hospital. This study was approved by the institutional review board of each institute under the Good Clinical Practice and was conducted with the ethical principles under the Declaration of Helsinki. The protocol of the present study was approved by the institutional review board of the Tohoku University Hospital (No. 133004) and was registered as UMIN Trial ID: UMIN000012369. This study was funded by the Japan Agency for Medical Research and Development (AMED) (No. 18lm0203047h0001).

LIPUS Therapy

Patients were placed in the left lateral position, and the probe was placed on the anterior chest wall to observe the heart and depict the ischemic site (Fig. 1A). By changing the setting to the ultrasound therapeutic mode, the depiction range became the treatment range. The ischemic area was determined in advance by invasive functional evaluation or stress myocardial perfusion imaging. Based on the preliminary study, the conditions of the LIPUS therapy in the trial were as follows; scanning beam with sector-type probe, frequency 1.875 MHz, intensity 0.25 MPa, transmission wave number 32 each, pulse repetitive frequency (PRF) 1 kHz, and target depth 6–8 cm.^6,11 LIPUS was applied for 20 min per cross-section, and was irradiated for 3 cross-sections from the base to the apex of the heart (mitral valve, papillary muscle, and apex levels) at an interval of 5 min (Fig. 1A). One session consisted of the LIPUS therapy every other day for 3 days. The study protocol with the first and second series is shown in Fig. 1B. In the first series, after the screening period, the LIPUS therapy and sham treatment were performed in a double-blind manner for patients and physicians, and only the un-blinded sonographer (physician) knew the therapy option. In the second series, 3 months after the first series, additional LIPUS therapy was applied to all patients. Efficacy outcomes were evaluated at 3 months after the first series, while safety outcome at one year after the second series (Fig. 1B).

Endpoints

The primary endpoint was weekly use of nitroglycerin at 3 months after the therapy. The secondary endpoints included chest pain frequency, CCS class score, 6-min walking distance, stress myocardial perfusion imaging, echocardiography, cardiac MRI, and adverse events. Weekly use of nitroglycerin, chest pain frequency, and CCS class score were recorded by individual patient in dedicated notebooks received after the registration, and at the follow-up period, collected by blinded clinical research coordinator. Adverse events included all-cause death and major adverse cardiovascular events (MACE) including a composite of cardiovascular death, non-fatal myocardial infarction, and hospitalization due to unstable angina or heart failure. Regarding the analysis of long-term prognosis, we analyzed not only the cases that completed follow-up, but also all the cases that received the therapy at least once in this study. As an evaluation of myocardial ischemia by stress myocardial perfusion imaging, the summed difference score (SDS) of the treatment area and the change in the ischemic amount before and 3 months after the treatment were calculated. Ischemic area was determined by prior invasive functional evaluation or stress myocardial perfusion imaging, and the analysis area of the heart was divided into 17 segments, and only the treatment-targeted area was extracted and analyzed.¹⁵

Post-hoc Analysis

In addition, we evaluated the correlation in stress myocardial perfusion imaging between the extent of baseline myocardial ischemia and post-treatment changes in the ischemia. This correlation analysis was performed to evaluate the effect of the LIPUS therapy when applied twice, between baseline and 6 months after the therapy.

Statistical Analysis

For the statistical analysis of primary and secondary endpoints, the mean value of change before and after the LIPUS therapy and the confidence interval were estimated, and comparisons were made between the 2 groups using the t-test. The Wald method was used for the comparison of the proportion of improved cases after the treatment and the estimation of the confidence interval. MACE and all-cause death were compared as cumulative incidence using Gray’s test where dropout due to death from non-cardiovascular causes or non-MACE adverse events were treated as a competing risk. For the estimation of the hazard ratio and P-value, the Fine and Gray model, which is an extension hazard model of the Cox's proportional hazards model, was used. Point estimates and 95% confidence intervals for adverse event withdrawal rates were calculated for each group at 450 days after the initial treatment. P value less than 0.05 was considered to be statistically significant.

Baseline Patient Characteristics

Baseline patient characteristics are shown in Table 1. Among the 64 patients enrolled in the trial, 33 were assigned to the LIPUS group and 31 to the placebo group (Fig. 1C). After the randomization, 2 in the LIPUS group did not complete the planned protocol due to withdrawal of consent, while 6 in the placebo group did not complete the trial (exacerbation of complications in 1, withdrawal of consent in 4, and death in 1 due to acute aortic dissection). Thus, 31 patients in the LIPUS group and 25 in the placebo group were analyzed for efficacy and safety endpoints (Fig. 1C). There were no significant differences in baseline patient characteristics between the 2 groups, expect for the incidence of atrial arrhythmias and diastolic blood pressure.

Primary Endpoint

The average age of the LIPUS group was 70 year-old and that of the placebo group 73.5 (Table 1). The average weekly use of nitroglycerin was 5.5 in the LIPUS group and 5.9 in the placebo group, and the average CCS class score was 2.4 in the LIPUS group and 2.6 in the placebo group. The average weekly use of nitroglycerin (times/week) decreased from 5.50 to 2.44 in the LIPUS group and from 5.94 to 2.83 in the placebo group (Fig. 2A). The changes in the weekly use of nitroglycerin were − 3.06 (95% CI: -4.481 to -1.648) in the LIPUS group (P < 0.01) and − 3.10 (95% CI: -4.848 to -1.356) in the placebo group (P < 0.01), with no difference between the 2 groups (P = 0.97). Similarly, there was no significant difference between the 2 groups in the proportion of patients whose average weekly use of nitroglycerin improved (P = 0.14).

Secondary Endpoints

CCS class score and average weekly frequency of chest pain decreased significantly but equally in the 2 groups (Table 2). Treadmill exercise test, 6-min walk distance, echocardiography, and cardiac MRI also showed no significant difference between the 2 groups (Table 2). Echocardiographic wall motion abnormalities were − 0.41 (-2.622-1.802, N = 30) in the LIPUS group and 0.18 (-2.406-2.776, N = 26) in the placebo group, which did not change from pre-treatment level (at the time of screening) in both groups (P = 0.72). Importantly, in stress myocardial perfusion imaging, the average extent of myocardial ischemia decreased from 13.71 to 12.84 in the LIPUS group, but increased from 6.41 to 8.48 in the placebo group (P = 0.18) (Fig. 2B).

Post-hoc Analysis

In this trial, we noted that there was a significant difference in the extent of baseline myocardial ischemia between the 2 groups. When we compared the patients with the extent of myocardial ischemia less than 30% of the left ventricle, we found that myocardial ischemia improved depending on the extent of baseline myocardial ischemia only in the LIPUS group (P < 0.01) but not in the placebo group (Appendix Figure A). Appendix Figure B shows representative images of a patient who showed improvement in myocardial ischemia in response to the LIPUS therapy.

Adverse Events

All-cause death was observed in 1 of 32 patients (3.1%) in the LIPUS group and in 4 of 29 patients (13.8%) in the placebo group (95% CI: 0.027 to 1.922, HR 0.23, P = 0.17) (Table 3). All-cause death tended to be improved in the LIPUS groups as compared with the placebo group (P = 0.17, HR 0.23) (Fig. 2C). MACE was documented in 4 of 32 patients (12.5%) in the LIPUS group and in 5 of 29 patients (17.2%) in the placebo group (95% CI: 0.192 to 2.587, HR 0.71, P = 0.60) (Table 3). There was no difference in MACE between the 2 groups (P = 0.60, HR 0.71) (Fig. 2D).

There were 7 device defects occurred during the treatment period (6 in the LIPUS group and 1 in the placebo group), which were immediately repaired. In this trial, there were no serious health damages related to the LIPUS therapy.

In the present study, we conducted a pilot trial to examine the efficacy and safety of the LIPUS therapy for patients with refractory angina. We found no significant differences in the primary subjective endpoints between the 2 groups. There was no serious adverse effect of the LIPUS therapy. To the best of our knowledge, this is the first clinical trial to address the efficacy and safety of the LIPUS therapy in patients with refractory angina.

In the past clinical trials for chronic coronary syndrome, most of the investigators focused on 2 major outcomes, including frequency of chest pain and long-term prognosis.¹⁶ In terms of frequency of chest pain, although there are some studies showing that PCI and optimal medical therapy (OMT; e.g. beta-blockers) improved QOL of stable angina patients,¹⁷ the ORBITA trial clearly demonstrated that the placebo effects are substantially involved in the treatment of chronic coronary syndrome.⁵ On the other hand, for the prognosis of chronic coronary syndrome, there are still major debates. In the ISCHEMIA trial with chronic coronary syndrome patients with moderate to severe ischemia, there was no difference in long-term prognosis between the intervention group treated with PCI and/or CABG and the conservative medical treatment group.³ In the present study, the primary endpoint was weekly nitroglycerin use with the aim of improving QOL in chronic coronary syndrome patients, which was dependent on subjective perception.⁵ In fact, in this study, weekly nitroglycerin use, CCS score, and chest pain frequency were all significantly but equally improved in both groups, indicating that the placebo effects were involved in the subjective endpoints, as in the ORBITA trial.⁵ However, importantly, this study also included objective secondary assessments such as stress myocardial perfusion imaging and prognosis. In these objective secondary endpoints, we could not reveal the statistically significant efficacy of the LIPUS therapy.

Based on these results, we consider that the efficacy of the LIPUS therapy was not shown in the present protocol. However, by analyzing myocardial perfusion imaging in individual cases, we found that some cases showed improvement in myocardial ischemia that could be regarded as a “responder”. In order to assess these cases, we performed an additional post-hoc analysis after adjusting the baseline myocardial ischemic volume. We found a significant correlation between the extent of baseline myocardial ischemia and the anti-ischemic effect of the LIPUS therapy. Furthermore, the LIPUS therapy tended to improve long-term prognosis as compared with the placebo group. From these results, we consider that a next pivotal trial with a larger number of patients and objective endpoints is required for future evaluation of the LIPUS treatment.

Mechanistically, we need to consider whether the total amount of LIPUS irradiation in the present study was enough to exert sufficient therapeutic effects. In the present trial, LIPUS was applied for 3 cross-sections for 20 min each from the base to the apex of the heart 3 days in a week. The similar conditions of the LIPUS therapy have been shown to exert eNOS-mediated angiogenic effects in porcine model of chronic myocardial ischemia and mouse model of acute myocardial infarction.^6,11 However, compared with these experimental studies with animal models, the angiogenic effects of the LIPUS therapy may not be sufficient for humans. Indeed, we also observed that repetitive LIPUS irradiation upregulated eNOS in mouse models of pressure-overload heart failure¹⁸ and diabetes-induced heart failure with preserved ejection fraction.¹⁹ In addition, we have recently confirmed that the LIPUS therapy on failing right ventricle (6 times in 2 consecutive weeks) was effective in a mouse model of pulmonary artery banding (PAB) and a rat model of Sugen/hypoxia (SU/Hx).²⁰ We also have demonstrated the effectiveness of “whole-brain” irradiation of the LIPUS therapy in mouse models of cerebrovascular dementia,²¹ cerebral infarction,²² and Alzheimer’s disease,²¹ where eNOS plays a pivotal role. Moreover, we have recently conducted a randomized, double-blind, placebo-controlled pilot trial of the LIPUS therapy for early stage of Alzheimer’s disease.²³ We found that the LIPUS therapy tended to suppress cognitive impairment at 24, 48, and 72 weeks as compared with the placebo group.²³ Thus, irradiation to the entire heart, that is “whole-heart” irradiation strategy, may be considered for the next pivotal trial.

Several limitations should be mentioned for the present study. First, as discussed above, we need to define objective findings, especially myocardial flow-related data, as objective primary endpoint. Second, the number of patients was small for statistical validation. Third, as discussed above, in order to enhance the anti-ischemic effects, repetitive performance of the LIPUS therapy for the whole heart needs to be considered for the next pivotal trial. All these considerations need to be included when designing the protocol of the next pivotal trial.

In summary, in the present pilot trial, we demonstrate the safety but not the additional efficacy of the LIPUS therapy for patients with refractory angina pectoris treated with optimal medical therapy. The present findings need to be further examined in the next pivotal trial with a large number of patients and modified protocols of the LIPUS therapy with objective endpoints.

Acknowledgements

The present study was conducted in part by the grant from the Japan Agency for Medical Research and Development (No. 18lm0203047h0001). We thank Katsumi Miyauchi, M.D., Ph.D and Kiyoshi Takasu, M.D., Ph.D., Juntendo University Graduate School of Medicine, Tokyo, Japan, and Hirokuni Akahori, M.D., Ph.D., Hyogo Medical University Graduate School of Medicine, Nishinomiya, Japan. We also thank Tomonori Ishii, Shoko Otomo, and Yuko Sawada, Department of Clinical Trial Implementation, Clinical Research, Innovation and Education Center, Tohoku University Hospital (CRIETO), for coordinating the trial, Koji Ikeda, Fumie Abe, Karin Ono, Satoki Kadota, Manami Hoshi, and Yoshimasa Yamazaki, CRIETO, for supporting the trial, and Airi Takagi and Takuhiro Yamaguchi, CRIETO, for statistical analysis. Appreciation is also expressed to all patients and their families who made our work possible.

Author contributions

K.I., T.O., R.K., K.E., Y.K., K.H., Y.H., K.N., T.S., J.T., H.K., S.Y., and H.S. contributed to conduction of the RCT. Y.O., T.N., Y.O., H.D., N.H., T.M., T.C., Y.F., and K.T. contributed to patient enrollment.

Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: A review. JAMA. 2022;327:662-675. doi:10.1001/jama.2022.0358.
Gulati M, Levy PD, Mukherjee D, et al. 2021AHA/ACC/ASE/CHEST/SAEM/SCCT/ SCMR guideline for the evaluation and diagnosis of chest pain: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144:e368-e454. doi:10.1161/CIR.0000000000001030.
Maron DJ, Hochman JS, Reynolds HR, et al, ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382:1395-1407. doi:10.1056/NEJMoa1915922.
Boden WE, O'Rourke RA, Teo KK, et al, COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16. doi:10.1056/NEJMoa070829.
Al-Lamee R, Thompson D, Dehbi HM, et al, ORBITA investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31-40. doi:10.1016/S0140-6736(17)32714-9.
Hanawa K, Ito K, Aizawa K, et al. Low-intensity pulsed ultrasound induces angiogenesis and ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia. PLoS One. 2014;9:e104863. doi:10.1371/journal.pone.0104863.
Barzelai S, Sharabani-Yosef O, Holbova R, et al. Low-intensity ultrasound induces angiogenesis in rat hind-limb ischemia. Ultrasound Med Biol. 2006;32:139–145. doi: 10.1016/j.ultrasmedbio.2005.08.010.
Mizrahi N, Seliktar D, Kimmel E. Ultrasound-induced angiogenic response in endothelial cells. Ultrasound Med Biol. 2007;33:1818–1829. doi: 10.1016/j.ultrasmedbio.2007.05.007.
Parton RG. Cell biology. Life without caveolae. Science. 2001;293:2404–2405. doi: 10.1126/science.1065677.
Parton RG, del Pozo MA. Caveolae as plasma membrane sensors, protectors and organizers. Nat Rev Mol Cell Biol. 2013;14:98–112. doi: 10.1038/nrm3512.
Shindo T, Ito K, Ogata T, et al. Low-intensity pulsed ultrasound enhances angiogenesis and ameliorates left ventricular dysfunction in a mouse model of acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2016;36:1220-1229. doi:10.1161/ATVBAHA.115.306477.
Davies PF. Flow-mediated endothelial mechanotransduction. Physiol Rev. 1995;75:519-60. doi: 10.1152/physrev.1995.75.3.519.
Yu J, Bergaya S, Murata T, et al. Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest. 2006;116:1284–1291. doi: 10.1172/JCI27100.
Shindo T, Shimokawa H. Therapeutic angiogenesis with sound waves. Ann Vasc Dis. 2020;13:116-125. doi:10.3400/avd.ra.20-00010.
Partridge JB, Anderson HR. Left ventricular anatomy: its nomenclature, segmentation, and planes of imaging. Clin Anat. 2009;22:77-84. doi:10.1002/ca.20646.
Davies A, Fox K, Galassi AR, et al. Management of refractory angina: an update. Eur Heart J. 2021;42:269-283. doi:10.1093/eurheartj/ehaa820.
Bech GJ, Bruyne BD, Pijls NH, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001;103:2928-34. doi:10.1161/01.cir.103.24.2928.
Ogata T, Ito K, Shindo T, et al. Low-intensity pulsed ultrasound enhances angiogenesis and ameliorates contractile dysfunction of pressure-overloaded heart in mice. PLoS One. 2017;12:e0185555. doi:10.1371/journal.pone.0185555.
Monma Y, Shindo T, Eguchi K, et al. Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice -A possible novel therapy for HFpEF. Cardiovasc Res. 2021;117:1325-1338. doi:10.1093/cvr/cvaa221.
Nakata T, Shindo T, Ito K, et al. Beneficial effects of low-intensity pulsed ultrasound on right ventricular dysfunction in animal models. JACC Basic Transl Sci. 2022; in press.
Eguchi K, Shindo T, Ito K, et al. Whole-brain low-intensity pulsed ultrasound therapy markedly improves cognitive dysfunctions in mouse models of dementia - Crucial roles of endothelial nitric oxide synthase. Brain Stimul. 2018;11:959-973. doi:10.1016/j.brs.2018.05.012.
Ichijo S, Shindo T, Eguchi K, et al. Low-intensity pulsed ultrasound therapy promotes recovery from stroke by enhancing angio-neurogenesis in mice in vivo. Sci Rep. 2021;11:4958. doi:10.1038/s41598-021-84473-6.
Shimokawa H, Shindo T, Ishiki A, et al. A pilot study of whole-brain low-intensity pulsed ultrasound therapy for early stage of Alzheimer's disease (LIPUS-AD): A randomized, double-blind, placebo-controlled trial. Tohoku J Exp Med. 2022. doi: 10.1620/tjem.2022.J078.

Table 1. Baseline Patient Characteristics

	LIPUS Group (N=31)	Placebo Group (N=27)	P-value
Age, years	70.0±11.3	73.5±11.7	0.25
Sex
Female	6 (19.4 %)	10 (37.0 %)	0.15
Male	25 (80.6 %)	17 (63.0 %)
Comorbidities
Hypertension	29 (93.5 %)	24 (88.9 %)	0.66
Hyperlipidemia	27 (87.1 %)	23 (85.2 %)	1.00
Diabetes mellitus	22 (71.0 %)	18 (66.7 %)	0.78
Heart failure	9 (29.0 %)	12 (44.4 %)	0.28
Stroke	1 (3.2 %)	3 (11.1 %)	0.33
Myocardial infarction	1 (3.2 %)	0 (0.0 %)	1.00
Valvular disease	3 (9.7 %)	4 (14.8 %)	0.69
PAD / Aortic aneurysm	10 (32.3 %)	13 (48.1 %)	0.28
COPD/Respiratory disease	9 (29.0 %)	4 (14.8 %)	0.22
Atrial fibrillation/Arrhythmia	5 (16.1 %)	11 (40.7 %)	0.04
Kidney disease/Renal dysfunction	12 (38.7 %)	11 (40.7 %)	1.00
Digestive disease	7 (22.6 %)	6 (22.2 %)	1.00
Medications
Aspirin/P2Y12 inhibitors	31 (100.0 %)	25 (92.6 %)	0.21
Beta-blockers	28 (90.3 %)	24 (88.9 %)	1.00
Calcium channel blockers	20 (64.5 %)	14 (51.9 %)	0.42
Renin-angiotensin system inhibitors	23 (74.2 %)	16 (59.3 %)	0.27
Lipid-lowering therapy	26 (83.9 %)	24 (88.9 %)	0.71
Antidiabetic drugs	15 (48.4 %)	12 (44.4 %)	0.80
SGLT₂ inhibitors	4 (12.9 %)	0 (0.0 %)	0.12
Nitroglycerin/Vasodilators	31 (100.0 %)	27 (100.0 %)	-
Loop diuretic/V₂ receptor antagonists	11 (35.5 %)	10 (37.0 %)	1.00
Mineralocorticoid receptor antagonists	2 (6.5 %)	5 (18.5 %)	0.23
Oral anticoagulants	4 (12.9 %)	8 (29.6 %)	0.19
Antiarrhythmic drugs	1 (3.2 %)	3 (11.1 %)	0.33
Digoxin	1 (3.2 %)	0 (0.0 %)	1.00
Vital signs
Systolic blood pressure, mmHg	127.5±18.1	123.2±18.4	0.38
Diastolic blood pressure, mmHg	69.7±10.4	64.7±7.7	0.05
Heart rate, beats per min	69.3±13.3	64.5±11.6	0.15
Height, cm	161.3±7.7	158.9±9.4	0.29
Body weight, kg	64.0±14.7	62.4±8.6	0.62
BMI, kg/m²	24.4±4.4	24.7±3.0	0.76
Echocardiography 　LVEF, % Laboratory data	53.5±13.2	53.1±12.0	0.90
Creatinine, mg/dL	2.4±3.0	2.1±2.8	0.67
LDL-cholesterol, mg/dL	80.3±21.8	81.5±25.2	0.85
HbA1c, %	6.7±1.0	6.7±1.1	0.77
CRP, mg/dL	0.34±0.37	0.28±0.39	0.61
BNP, pg/dL	366.2±771.8	265.1±422.3	0.55

Results are presented as means±SD. Categorical variables are presented as counts and percentages.

Table 2. Clinical Outcomes

	LIPUS Group (N=31)	Placebo Group (N=27)	P-value
Primary endpoint
Weekly nitroglycerin use	-3.06 (-4.481, -1.648)	-3.10 (-4.848, -1.356)	0.97
Secondary endpoints
CCS class score	-0.50 (-0.773, -0.227)	-0.54 (-0.824, -0.253)	0.84
Chest pain, per week	-3.98 (-5.796, -2.156)	-5.25 (-9.057, -1.443)	0.52
Treadmill exercise load, kcal	-2.40 (-9.041, 4.233)	3.87 (-1.982, 9.726)	0.16
Treadmill exercise load time, min	-0.55 (-1.639, 0.538)	0.37 (-0.548, 1.295)	0.21
6-min walk distance, m	-0.7 (-52.60, 51.20)	12.3 (-28.12, 52.72)	0.66
Stress myocardial perfusion imaging (SDS)	0.31 (-1.149, 1.770)	0.00 (-1.969, 1.969)	0.79
Echocardiography LVEF, %	-0.41 (-2.622, 1.802)	0.18 (-2.406, 2.776)	0.72
Cardiac MRI LVEF, %	4.03 (-10.520, 18.573)	2.98 (-4.109, 10.060)	0.84
Cardiac MRI stroke volume, mL	-7.1 (-24.63, 10.39)	13.3 (-1.10, 27.68)	0.07

Table 3. Clinical Outcomes (MACE)

Adverse events (510 days)
	LIPUS Group (N=32)	Placebo Group (N=29)	Hazard Ratio (95%CI)	P-value
All-cause death	1 (3.1%)	4 (13.8%)	0.23 (0.027-1.922)	0.17
MACE	4 (12.5%)	5 (17.2%)	0.71 (0.192-2.587)	0.59
Cardiovascular death	0 (0.0%)	1 (3.4%)	0.00 (-)	-
Non-fatal myocardial infarction	0 (0.0%)	1 (3.4%)	0.00 (-)	-
Hospitalization due to unstable angina/heart failure	4 (12.5%)	3 (10.3%)	1.21 (0.271-5.408)	0.80

There is NO Competing Interest.

AppendixFigure.pptx
Appendix Figure. Post-hoc Analysis of the LIPUS Therapy on Objective Outcome (A) Myocardial perfusion images in a representative case in response to the LIPUS therapy. (B) Correlation between the extent of baseline myocardial ischemia and that of post-treatment changes in myocardial ischemia evaluated by stress myocardial perfusion imaging.
LIPUSAnginaProtocol.docx

Download PDF

Version 1

posted

You are reading this latest preprint version

A Randomized, Double-blind, Placebo-controlled Pilot Trial of Low-intensity Pulsed Ultrasound Therapy for Refractory Angina Pectoris

Status:

Version 1

Abstract

Figures

Introduction

Methods

Study Protocols

LIPUS Therapy

Endpoints

Post-hoc Analysis

Statistical Analysis

Results

Baseline Patient Characteristics

Primary Endpoint

Secondary Endpoints

Post-hoc Analysis

Adverse Events

Discussion

Declarations

References

tables

Additional Declarations

Supplementary Files

Status:

Version 1